About US
Contact us
-
While mRNA saved the COVID-19 day, GSK and Sanofi vaccines likely safe beyond pandemic: analystsFew knew about mRNA technology before the pandemic ushered the novel approach to the forefront of the fight against COVID-19. But while mRNA shots sailed through testing and have reached hundreds of2021/6/14
-
Long-suffering Dendreon finds new avatar as contract manufacturer for cell therapy partnersFiling for bankruptcy in 2014 might have seemed the end for Dendreon.But seven years later—and three rounds of being bought and sold—the company has resurfaced. This week,Dendreonrevealedplans to est2021/6/14
-
Novartis extends operations at U.K. plant for another year, keeping some 200 workers on boardAs Novartis shifts away from the production of older, less profitable drugs, the drugmaker has placeda slew of production facilitiesin the cost-cutting crosshairs. But with the company facingincrease2021/6/11
-
Vexed by vectors: How COVID-19 vaccine and cell and gene players are tackling the viral vector bottleneckBristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are unite2021/6/11
-
Change to Gilead assistance program threatens PrEP access, HIV advocates sayDr. John Carlo is concerned that patients at Prism Health North Texas who rely on the health care safety net will soon be struggling even more to stay on PrEP, a medication that prevents HIV transmis2021/6/9
-
Biogen's hefty Aduhelm cost sparks even more talk of a drug pricing crackdown. But will it happen?A $56,000 annual price tag for a drug with questionable credentials? Let the feeding frenzy begin for politicians who have long supported drug price reform and now have a poster child for their cause2021/6/9
-
ASCO: Merck's Keytruda targets Pfizer's shaky Sutent post-surgery use in kidney cancerSince 2017, Pfizer’s kinase inhibitor Sutent has been approved to help prevent tumors from returning in high-risk kidney cancer patients after surgery. But its efficacy and safety are far from ideal.2021/6/7
-
It had to happen: Ex-Celgene shareholders sue Bristol Myers Squibb for $6.4B in lost CVR cash, claiming 'blatant misconduct'It wasn’t so much a question of whetherBristol Myers Squibb would be taken to court by former Celgene shareholders. It was more a question of when. The answer came Thursday in U.S. District Court-Sou2021/6/7
-
Fierce Pharma Asia—Amgen-Kyowa Kirin eczema deal; J&J, Legend's CAR-T; CStone's PD-L1Amgen shelled out $400 million upfront for ex-Japan rights to Kyowa Kirin's anti-OX40 atopic dermatitis candidate. Johnson & Johnson and Legend Biotech's anti-BCMA CAR-T therapy turnedup more mul2021/6/3
-
Regeneron leaps ahead in COVID-19 antibody race, scoring FDA nod for lower dose and subcutaneous injectionWhen Eli Lilly gained emergency use approval for its COVID-19 antibody treatment last October, it was a major triumph for a company aiming to satisfy a desperate need around the world. But eight mont2021/6/3